Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Milan Vujčić et al., adding:
“Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis
A 72-year-old woman with IgG kappa myeloma and gastrointestinal angiodysplasia had recurrent life-threatening bleeding refractory to factor concentrates, immunoglobulin, plasmapheresis and endoscopy.
Subcutaneous emicizumab with octreotide and ongoing anti-myeloma therapy achieved complete cessation of bleeding despite persistently undetectable von Willebrand factor activity, with 12 months transfusion-free and ECOG 0.”
Title: Multimodal management of refractory gastrointestinal bleeding in myeloma-associated acquired von Willebrand syndrome: a role for emicizumab prophylaxis
Authors: Milan Vujčić, Sanja Madunić, P. Jasminka Jakelić, Marija Petrić, Davor Galušić, Ena Ranković, Ana Boban
Other posts about Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience